Txr1: A transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes

Genes and Development

Volumn 20, Issue 15, 2006, Pages 2082-2095

  Lih, Chih Jian ^a   Wei, Wensheng ^a   Cohen, Stanley N ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; CD47; Microarray; Taxanes; Thrombospondin 1; Txr1

Indexed keywords

CD47 ANTIGEN; PACLITAXEL; TAXANE DERIVATIVE; THROMBOSPONDIN 1;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CLONING; CYTOTOXICITY; DOWN REGULATION; GENE; GENE CONTROL; GENE EXPRESSION; GENE LOCATION; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; RETROVIRUS; TXR1 GENE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BRIDGED COMPOUNDS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; TAXOIDS; THROMBOSPONDIN 1;

EID: 33746542655     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1441306     Document Type: Article

References (50)

1. Bae, V.L., Jackson-Cook, C.K., Maygarden, S.J., Plymate, S.R., Chen, J., and Ware, J.L. 1998. Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate 34: 275-282.
2. Berns, K., Hijmans, E.M., Mullenders, J., Brummelkamp, T.R., Velds, A., Heimerikx, M., Kerkhoven, R.M., Madiredjo, M., Nijkamp, W., Weigelt, B., et al. 2004. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428: 431-437.
3. 1. J. Cell Biol. 127: 1129-1137.
4. Bradley, G. and Ling, V. 1994. P-Glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev. 13: 223-233.
5. Brown, E.J. and Frazier, W.A. 2001. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 11: 130-135.
6. Cheung, H.W., Ling, M.T., Tsao, S.W., Wong, Y.C., and Wang, X. 2004. Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 25: 881-887.
7. Damber, J.E., Vallbo, C., Albertsson, P., Lennernas, B., and Norrby, K. 2006. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother. Pharmacol. 58: 354-360.
8. de Fraipont, F., Nicholson, A.C., Feige, J.J., and Van Meir, E.G. 2001. Thrombospondins and tumor angiogenesis. Trends Mol. Med. 7: 401-407.
9. 3 function through integrin-associated protein. J. Cell Biol. 135: 533-544.
10. Gao, A.G., Lindberg, F.P., Finn, M.B., Blystone, S.D., Brown, E.J., and Frazier, W.A. 1996b. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J. Biol. Chem. 271: 21-24.
11. Giannakakou, P., Sackett, D.L., Kang, Y.K., Zhan, Z., Buters, J.T., Fojo, T., and Poruchynsky, M.S. 1997. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272: 17118-17125.
12. Harada, H., Nakagawa, K., Saito, M., Kohno, S., Nagato, S., Furukawa, K., Kumon, Y., Hamada, K., and Ohnishi, T. 2003. Introduction of wild-type p53 enhances thrombospondin-1 expression in human glioma cells. Cancer Lett. 191: 109-119.
13. Haviv, F., Bradley, M.F., Kalvin, D.M., Schneider, A.J., Davidson, D.J., Majest, S.M., McKay, L.M., Haskell, C.J., Bell, R.L., Nguyen, B., et al. 2005. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: Design, synthesis, and optimization of pharmacokinetics and biological activities. J. Med. Chem. 48: 2838-2846.
14. Horwitz, S.B. 1992. Mechanism of action of taxol. Trends Pharmacol. Sci. 13: 134-136.
15. Horwitz, S.B., Cohen, D., Rao, S., Ringel, I., Shen, H.J., and Yang, C.P. 1993. Taxol: Mechanisms of action and resistance. J. Natl. Cancer Inst. Monogr. (15) 55-61.
16. Jimenez, B., Volpert, O.V., Crawford, S.E., Febbraio, M., Silverstein, R.L., and Bouck, N. 2000. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. 6: 41-48.
17. Kavallaris, M., Kuo, D.Y., Burkhart, C.A., Regl, D.L., Norris, M.D., Haber, M., and Horwitz, S.B. 1997. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J. Clin. Invest. 100: 1282-1293.
18. Kimchi, A. 2003. Antisense libraries to isolate tumor suppressor genes. Methods Mol. Biol. 222: 399-412.
19. Li, L. and Cohen, S.N. 1996. Tsg101: A novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 85: 319-329.
20. Li, Z., He, L., Wilson, K., and Roberts, D. 2001. Thrombospondin-1 inhibits TCR-mediated T lymphocyte early activation. J. Immunol. 166: 2427-2436.
21. Li, K., Yang, M., Yuen, P.M., Chik, K.W., Li, C.K., Shing, M.M., Lam, H.K., and Fok, T.F. 2003. Thrombospondin-1 induces apoptosis in primary leukemia and cell lines mediated by CD36 and Caspase-3. Int. J. Mol. Med. 12: 995-1001.
22. Lu, Q., Wei, W., Kowalski, P.E., Chang, A.C., and Cohen, S.N. 2004. EST-based genome-wide gene inactivation identifies ARAP3 as a host protein affecting cellular susceptibility to anthrax toxin. Proc. Natl. Acad. Sci. 101: 17246-17251.
23. Manna, P.P. and Frazier, W.A. 2004. CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A. Cancer Res. 64: 1026-1036.
24. Monzo, M., Rosell, R., Sanchez, J.J., Lee, J.S., O'Brate, A., Gonzalez-Larriba, J.L., Alberola, V., Lorenzo, J.C., Nunez, L., Ro, J.Y., et al. 1999. Paclitaxel resistance in non-small-cell lung cancer associated with β-tubulin gene mutations. J. Clin. Oncol. 17: 1786-1793.
25. Moss, J. and Vaughan, M. 1988. ADP-ribosylation of guanyl nucleotide-binding regulatory proteins by bacterial toxins. Adv. Enzymol. Relat. Areas Mol. Biol. 61: 303-379.
26. Ory, D.S., Neugeboren, B.A., and Mulligan, R.C. 1996. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. 93: 11400-11406.
27. Pan, K.H., Lih, C.J., and Cohen, S.N. 2002. Analysis of DNA microarrays using algorithms that employ rule-based expert knowledge. Proc. Natl. Acad. Sci. 99: 2118-2123.
28. Parekh, H. and Simpkins, H. 1996. Species-specific differences in taxol transport and cytotoxicity against human and rodent tumor cells. Evidence for an alternate transport system. Biochem. Pharmacol. 51: 301-311.
29. Primiano, T., Baig, M., Maliyekkel, A., Chang, B.D., Fellars, S., Sadhu, J., Axenovich, S.A., Holzmayer, T.A., and Roninson, I.B. 2003. Identification of potential anticancer drug targets through the selection of growth-inhibitory genetic suppressor elements. Cancer Cell 4: 41-53.
30. Quesada, A.J., Nelius, T., Yap, R., Zaichuk, T.A., Alfranca, A., Filleur, S., Volpert, O.V., and Redondo, J.M. 2005. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ. 12: 649-658.
31. Ranganathan, S., Benetatos, C.A., Colarusso, P.J., Dexter, D.W., and Hudes, G.R. 1998. Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br. J. Cancer 77: 562-566.
32. Reiher, F.K., Volpert, O.V., Jimenez, B., Crawford, S.E., Dinney, C.P., Henkin, J., Haviv, F., Bouck, N.P., and Campbell, S.C. 2002. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int. J. Cancer 98: 682-689.
33. Rowinsky, E.K. 1997. Paclitaxel pharmacology and other tumor types. Semin. Oncol. 24: S19-1-S19-12.
34. Sargiannidou, I., Zhou, J., and Tuszynski, G.P. 2001. The role of thrombospondin-1 in tumor progression. Exp. Biol. Med. (Maywood) 226: 726-733.
35. Scherf, U., Ross, D.T., Waltham, M., Smith, L.H., Lee, J.K., Tanabe, L., Kohn, K.W., Reinhold, W.C., Myers, T.G., Andrews, D.T., et al. 2000. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24: 236-244.
36. Schmidt, M., Lu, Y., Parant, J.M., Lozano, G., Bacher, G., Beckers, T., and Fan, Z. 2001. Differential roles of p21Waf1 and p27Kip1 in modulating chemosensitivity and their possible application in drug discovery studies. Mol. Pharmacol. 60: 900-906.
37. Sid, B., Sartelet, H., Bellon, G., El Btaouri, H., Rath, G., Delorme, N., Haye, B., and Martiny, L. 2004. Thrombospondin 1: A multifunctional protein implicated in the regulation of tumor growth. Crit. Rev. Oncol. Hematol. 49: 245-258.
38. Volpert, O.V. and Alani, R.M. 2003. Wiring the angiogenic switch: Ras, Myc, and Thrombospondin-1. Cancer Cell 3: 199-200.
39. Volpert, O.V., Pili, R., Sikder, H.A., Nelius, T., Zaichuk, T., Morris, C., Shiflett, C.B., Devlin, M.K., Conant, K., and Alani, R.M. 2002a. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2: 473-483.
40. Volpert, O.V., Zaichuk, T., Zhou, W., Reiher, F., Ferguson, T.A., Stuart, P.M., Amin, M., and Bouck, N.P. 2002b. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat. Med. 8: 349-357.
41. Waclavicek, M., Majdic, O., Stulnig, T., Berger, M., Baumruker, T., Knapp, W., and Pickl, W.F. 1997. T cell stimulation via CD47: Agonistic and antagonistic effects of CD47 monoclonal antibody 1/1A4. J. Immunol. 159: 5345-5354.
42. 2/M arrest and apoptosis. Nat. Med. 2: 72-79.
43. Xie, W., Li, L., and Cohen, S.N. 1998. Cell cycle-dependent subcellular localization of the TSG101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency. Proc. Natl. Acad. Sci. 95: 1595-1600.
44. Xu, X., Leo, C., Jang, Y., Chan, E., Padilla, D., Huang, B.C., Lin, T., Gururaja, T., Hitoshi, Y., Lorens, J.B., et al. 2001. Dominant effector genetics in mammalian cells. Nat. Genet. 27: 23-29.
45. Yang, Q.W., Liu, S., Tian, Y., Salwen, H.R., Chlenski, A., Weinstein, J., and Cohn, S.L. 2003. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res. 63: 6299-6310.
46. Yap, R., Veliceasa, D., Emmenegger, U., Kerbel, R.S., McKay, L.M., Henkin, J., and Volpert, O.V. 2005. Metronomic low-dose chemotherapy boosts CD95-dependent anti-angiogenic effect of the thrombospondin peptide ABT-510: A complementation anti-angiogenic strategy. Clin. Cancer Res. 11: 6678-6685.
47. Yoo, G.H., Piechocki, M.P., Ensley, J.F., Nguyen, T., Oliver, J., Meng, H., Kewson, D., Shibuya, T.Y., Lonardo, F., and Tainsky, M.A. 2002. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clin. Cancer Res. 8: 3910-3921.
48. Yoo, G.H., Lin, H.S., Iskander, A.J., Piechocki, M.P., Oliver, J., Kewson, D., Lonardo, F., Tainsky, M.A., Kim, H.R., Kim, H., et al. 2005. Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: A pilot study. Laryngoscope 115: 1938-1946.
49. Yujiri, T., Fanger, G.R., Garrington, T.P., Schlesinger, T.K., Gibson, S., and Johnson, G.L. 1999. MEK kinase 1 (MEKK1) transduces c-Jun NH2-terminal kinase activation in response to changes in the microtubule cytoskeleton. J. Biol. Chem. 274: 12605-12610.
50. Zhang, H., Pan, K.H., and Cohen, S.N. 2003. Senescence-specific gene expression fingerprints reveal cell-type-dependent physical clustering of up-regulated chromosomal loci. Proc. Natl. Acad. Sci. 100: 3251-3256.